The etiology of prostate cancer is not well understood. Established risk factors from epidemiologic studies include family history and geographic or ethnic origin; associations have also been noted with diet, lifestyle, occupation, and environment ( 1 , 2 ) . Although prostate cancer occurs with increased frequency in men carrying mutations in BRCA1, BRCA2, and other genes involved in DNA repair ( 3 ), the prevalence of such mutations is low, and only a small proportion of cases of this cancer can be attributable to them. Furthermore, for autosomal and X chromosome genes, the search for common variants that might define men at risk for prostate cancer has been frustrating ( 3 ), although some progress has been made recently ( 4 ) . Some studies have suggested the involvement of loci on sex chro mosomes, both X ( 5 -9 ) and Y ( 6 , 10 -15 ) . Because mutations or variants in sex chromosomes might alter the probabilities of having sons or daughters, we questioned whether the risk of this malignancy could be related to sex of offspring. Previous studies of this association have yielded conflicting results ( 16 -19 ) .
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We used proportional hazards models as implemented in SAS version 9.1 to estimate relative risks (RRs) and to control for covariates. Assumptions of proportionality were verifi ed by inspecting " lognegative-log " plots ( 23 ) and by testing each variable as a time-dependent product of its coded value (0,1) with length of follow-up. Observations were timed for each man from 9 months before the birth of the fi rst of his observed offspring until his death or the diagnosis of cancer at any site; survivors were censored on December 31, 2004. Covariates -i.e., variables altering the relative risk associated with lack of sons by at least 10% and/or independent predictors of prostate cancer at P <.05 or less -included the father's age at the start of follow-up (years, deviations from mean = 28); social class (a 6-point ordinal scale ( 21 ) based on the man's occupation at the most recently observed birth); and sets of mutually exclusive variables or dichotomies coded 0 (absent) or 1 (present), representing the man's year of birth (1950 or later, 1945 -1949, or 1940 -1944 , versus earlier), his education ( Ն 13 years versus less); rabbis/ students in Talmudic academies (yes versus no); wife's job status (high versus others); and ethnic origin, based on grandfather's place of birth (North Africa versus all others). Variables that failed to meet criteria for inclusion were year of birth of the fi rst observed offspring, categories of the man's year of birth before 1940, We surveyed vital status and cancer incidence in fathers from the Jerusalem Perinatal Study, a family-based research cohort. The methods and characteristics of the population have been described ( 20 -22 ) . In brief, from January 1, 1964, through December 31, 1976 , all 92 408 births to residents of western (i.e., Israeli) Jerusalem were recorded. Demographic information on parents and grandfathers was abstracted from birth certifi cates; this information was supplemented with data from medical records relating to the mother's pregnancy and the child's health, from interviews with mothers, and via data gleaned through surveillance of pediatric inpatients and the district health offi ce. The cohort was linked with Israel's Population Registry to trace both offspring and mothers in 2000 and to trace the fathers in 2005. Tracing involved verifying identity numbers (IDs) and obtaining a current address or ascertaining date of death. The IDs of the traced fathers were linked in 2005 to Israel's Cancer Registry. The study was approved by the institutional review boards at Hadassah Medical Center, religion (Muslim versus Jewish), wife's edu cation ( Ն 13, 9 -12, or 5 -8 years, versus others), one or more offspring with low birth weight (i.e., <2.5 kg) versus all offspring weighing more; one or more offspring with high birth weight (i.e., Ն 4.0 kg) versus all offspring weighing less; and any major birth defect (versus none) or any minor defect (versus none). To test for trend, we entered the numbers of offspring into the Cox models as ordinal variables, truncated at fi ve or more for total offspring and four or more for offspring of either sex. Two time-dependent variables were used, as dichotomies, for follow-up during calendar years 1991 -1995 and 1996 -2004 to control for changes in incidence that followed the introduction of testing with prostate-specifi c antigen (PSA) in 1991.
Prostate Cancer in Fathers With
The 91 467 live offspring in the Jerusalem Perinatal Study included 12 with unknown sex and 47 037 males (51.43%). We had traced 98.5% of offspring by 2005 and through them verifi ed 95.7% of their fathers ' IDs; these 38 995 IDs were then linked to Israel's Cancer Registry. We excluded 58 men with cancers diagnosed before their fi rst offspring's estimated date of conception and three with unknown dates of death, leaving 38 934 for analysis. Among these, there were 4026 men with invasive malignancies; they had sired 8526 offspring, of whom 51.70% were males. The men without cancer had 75 921 offspring, with 51.5% males.
A total of 712 men were diagnosed with invasive prostate cancer at the age of 42 -87 years (median = 68 years), after 7 -41 years of follow-up (median = 31). Their 1445 offspring included 48.58% males (95% confi dence interval [CI] = 46.00% to 51.16%). This crude sex ratio differed ( P = .023) from that of the offspring of the rest of the cohort (51.57%, 95% CI = 51.23% to 51.91%) and was also lower ( P = .0051) than that of the offspring sired by men who developed other malignancies (52.26%, 95% CI = 51.10% to 53.43%).
Estimates of the risk of prostate cancer in men without sons, conditional on the total numbers of offspring, are shown in Table 1 . Overall, there was a 40% increase in prostate cancer in men lacking sons. In subgroup analyses (data not shown), this increase was consistently associated with lack of sons; we observed relative risks similar to 40% across different age groups, ethnic groups, and social classes, as well as in men diagnosed both before and after 1991, when PSA came into use. The data in Table 1 show that the relative risk associated with absence of sons increased as the numbers of offspring increased.
We also investigated whether risk was associated with lack of daughters (data not shown in table). In men with exactly two offspring and a reference group who sired one offspring of each sex, those lacking daughters had RR = 1.11 (95% CI = 0.79 to 1.56, based on 53 cases in 3153 men) whereas those without sons had RR = 1.47 (95% CI = 1.06 to 2.04, P = .021). Similarly, in men with three or more offspring and a reference group of men who sired at least one of each sex, those without daughters showed RR = 1.09 (95% CI = 0.68 to 1.73, based on 20 cases in 1155 men), whereas the group lacking sons showed RR = 1.60 (95% CI = 1.05 to 2.45, P = .03). The small excess risk of prostate cancer in fathers lacking daughters was likely to be due to chance and did not strengthen with increasing numbers of offspring. Table 2 shows an analysis of the risk of prostate cancer that considers the numbers of offspring and numbers of sons and daughters as ordinal variables. There was a strong trend for a decrease in prostate cancer risk as the number of sons increased. Although there was no such trend for the number of daughters, the difference between numbers of sons and numbers of daughters is not formally statistically signifi cant because the confi dence limits for the two estimates of trend overlap.
Of the 712 fathers diagnosed with prostate cancer, 185 died during follow-up. In the whole cohort, the relative risk of mortality " with prostate cancer " associated with the lack of sons -i.e., regardless of immediate cause of death -was 1.59 (95% CI = 1.17 to 2.18, P = .0035), somewhat higher than the relative risk of prostate cancer incidence (i.e., 1.40). Regarding survival after diagnosis of prostate cancer in the 712 men, however, the relative risk of death associated with the lack of sons was 0.99 (95% CI = 0.72 to 1.34).
To assess specifi city of the association of lack of sons with the incidence of prostate cancer, we analyzed the age-adjusted incidence of malignancies at specifi c sites other than the prostate; none was statistically signifi cantly related to lack of sons (data not shown). The age-adjusted relative risk of cancer at all sites combined, excluding prostate cancer, was 0.95 (95% CI = 0.88 to 1.03) in men lacking a son compared with those who had at least one son. We also analyzed mortality from all causes (6324 deaths) in the cohort of 38 934 fathers; this outcome was also unrelated to the lack of sons (RR = 0.97, 95% CI = 0.91 to 1.02).
This study has several limitations. One is that we have no information about the offspring born to the same fathers before 1964 or after 1976. There is, however, no reason to suspect that the 712 men diagnosed with prostate cancer would have sired a different proportion of males outside of 1964 -1976 than during that period. Furthermore, any misclassifi cation within the group of men in which we observed no sons would have biased the relative risk toward the null. We also have no information on family history of prostate cancer, individual screening behavior, or measures
CONTEXT AND CAVEATS

Prior knowledge
Genes on the Y chromosome have been implicated in prostate cancer. Mutations in such genes have the potential to influence the sex ratio of the offspring of men carrying them.
Study design
Men who were fathers in a family-based research cohort in Israel were followed for up to 40 years after the birth of their children.
Contribution
Men with only daughters had a 40% higher risk of prostate cancer than men with at least one son.
Implications
The findings support hypotheses that Y chromosome loci are involved in prostate cancer. Further investigation of reproductive outcomes of men might provide additional information on genes involved in prostate cancer.
Limitations
Information on sex of offspring was determined over a single 13-year period, and men who had sons before or after that period would have been misclassified in the analysis. No information on individual screening behavior was available. The study analyzed a single population, limiting generalizability.
of disease progression, such as Gleason score. For example, if fathers of daughters had been screened more than fathers of sons, which might be one hypothetical explanation of our results, we should have seen risk related to the number of daughters, but we did not. Furthermore, had our results been explained by this type of differential screening, resulting in earlier diagnosis or overdiagnosis, we would have expected to see a spuriously decreased mortality (i.e., apparently better survival) in the men diagnosed with prostate cancer who lacked sons. We observed no such altered survival. The strongest evidence that our fi ndings are unlikely to be spurious comes from the data in Table 1 , which suggest that the biologic signifi cance of lack of sons -whatever it is that leads to increased risk of prostate cancer -becomes increasingly important as family size increases.
Overall, our fi ndings are consistent with hypotheses that tie Y chromosome loci to prostate cancer, although other explanations cannot be excluded. The Y chromosome, which is inherited from father to son, is extremely vulnerable to mutation because it undergoes minimal recombination with the X chromosome ( 24 -26 ) . Well-defi ned haplogroups in men with different geographic ancestries ( 24 , 27 ) have been associated with various diseases ( 28 ) . Lineages of Israeli Jews, including Ashkenazim, are similar to those found in the non-Jewish populations of Eastern Turkey, Iran, and northern Iraq; they differ from those prevalent in European nonJews ( 29 ) . Thus, if the increased risk of prostate cancer that we observed in men without sons turns out to refl ect an association with Y chromosome haplogroups, our fi ndings might be more relevant to populations in West Asia than to those in Europe or the United States. In another population, a recent study has shown that Y chromosome haplogroups found only in Japanese men are related to the risk of prostate cancer ( 15 ) .
Other evidence for involvement of loci on the Y chromosome comes from studies of prostate tumors. Loss of the Y chromosome is the most frequently observed cytogenetic abnormality in malignant prostate epithelium ( 6 , 12 ) , and although the Y chromosome is frequently lost in other tissues with aging, it is generally preserved in normal prostate tissue ( 12 ) , probably because some of its genes are essential for the prostate gland to function normally. The expression of some Y chromosomal genes -including TSPY, a multicopy gene implicated in gonadoblastoma, testicular, and prostate cancer ( 30 ) , and SRY , the master switch for sex determination ( 31 , 32 ) -is reduced through hypermethylation ( 14 ) in malignant prostate tissue ( 10 -13 ) . SRY negatively regulates the X chromosome -linked androgen receptor (AR) gene ( 33 ) ; thus its loss in the prostate would likely increase the gland's sensitivity to androgens. The AR's numerous other coactivators and corepressors include DAX1, the product of an X chromosome gene that is also involved in sex determination ( 31 , 32 , 34 ) , and BRCA1 ( 35 ); BRCA2 also plays a role in regulating the expression of the AR ( 36 ). The incidence of prostate cancer is increased in some ( 37 -40 ) but not all ( 41 , 42 ) families carrying mutations in BRCA1 or BRCA2. In such families, re gardless of whether they include men with prostate cancer, male carriers have a lower percentage of male offspring than the general population ( 43 , 44 ) . In two case -control studies, the prostate cancer patients reported fewer male siblings than control subjects ( 45 , 46 ) . These observations and our results suggest that some men with prostate cancer may carry abnormalities involving loci on the Y and/or X chromosomes or factors interacting with them. Further investigation of reproductive outcomes of men might throw light on prostate cancer and other malespecifi c malignancies.
